Literature DB >> 29661036

When migraine mimics stroke: A systematic review.

Alberto Terrin1, Giulia Toldo1, Mario Ermani1, Federico Mainardi2, Ferdinando Maggioni1.   

Abstract

BACKGROUND: Migraine with aura may mimic an acute ischemic stroke, so that an improper administration of thrombolytic treatment can expose migrainous patients to severe adverse effects.
METHODS: This systematic review quantifies the relevance of migraine with aura among stroke mimics, checking for thrombolysis' safety in these patients. We reviewed the literature after 1995, distinguishing from studies dealing with stroke mimics treated with systemic thrombolysis and those who were not treated with systemic thrombolysis.
RESULTS: Migraine with aura is responsible for 1.79% (CI 95% 0.82-3.79%) of all the emergency Stroke Unit evaluations and it represents 12.24% (CI 95% 6.34-22.31%) of stroke mimics in the group not treated with systemic thrombolysis. 6.65% (CI 95% 4.32-9.78%) of systemic thrombolysis administrations are performed in patients without an acute ischemic stroke. Migraine with aura is responsible for 17.91% of these (CI 95% 13.29-23.71%). The reported rate of adverse events seems extremely low (0.01%).
CONCLUSION: Migraine with aura is the third most common stroke mimic, following seizures and psychiatric disorders; it is responsible for about 18% of all improper thrombolytic treatments. Despite the absence of strong supporting data, thrombolysis in migraine with aura seems to be a procedure with an extremely low risk of adverse events.

Entities:  

Keywords:  Headache; aura; outcome; safety; thrombolysis

Mesh:

Year:  2018        PMID: 29661036     DOI: 10.1177/0333102418767999

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  8 in total

1.  A novel computed tomography perfusion-based quantitative tool for evaluation of perfusional abnormalities in migrainous aura stroke mimic.

Authors:  Antonio Granato; Laura D'Acunto; Miloš Ajčević; Giovanni Furlanis; Maja Ukmar; Roberta Antea Pozzi Mucelli; Paolo Manganotti
Journal:  Neurol Sci       Date:  2020-05-26       Impact factor: 3.307

2.  Clinical features of visual migraine aura: a systematic review.

Authors:  Michele Viana; Erling Andreas Tronvik; Thien Phu Do; Chiara Zecca; Anders Hougaard
Journal:  J Headache Pain       Date:  2019-05-30       Impact factor: 7.277

3.  Ischemic stroke with a preceding Trans ischemic attack (TIA) less than 24 hours and thrombolytic therapy.

Authors:  Nicolas Poupore; Dan Strat; Tristan Mackey; Ashley Snell; Thomas Nathaniel
Journal:  BMC Neurol       Date:  2020-05-19       Impact factor: 2.474

4.  ICHD-3 is significantly more specific than ICHD-3 beta for diagnosis of migraine with aura and with typical aura.

Authors:  Carl H Göbel; Sarah C Karstedt; Thomas F Münte; Hartmut Göbel; Sebastian Wolfrum; Elena R Lebedeva; Jes Olesen; Georg Royl
Journal:  J Headache Pain       Date:  2020-01-07       Impact factor: 7.277

5.  Sex Differences in Presentation of Stroke: A Systematic Review and Meta-Analysis.

Authors:  Mariam Ali; Hendrikus J A van Os; Nelleke van der Weerd; Jan W Schoones; Martijn W Heymans; Nyika D Kruyt; Marieke C Visser; Marieke J H Wermer
Journal:  Stroke       Date:  2021-12-14       Impact factor: 7.914

6.  Stroke unit demand in Norway - present and future estimates.

Authors:  Fredrik A Dahl; Mathias Barra; Kashif W Faiz; Hege Ihle-Hansen; Halvor Næss; Kim Rand; Ole Morten Rønning; Tone Breines Simonsen; Bente Thommessen; Angela S Labberton
Journal:  BMC Health Serv Res       Date:  2022-03-15       Impact factor: 2.655

7.  Stroke and cardiovascular risk factors among working-aged Finnish migraineurs.

Authors:  Marja-Liisa Sumelahti; Merika S Sumanen; Kari J Mattila; Lauri Sillanmäki; Markku Sumanen
Journal:  BMC Public Health       Date:  2021-06-07       Impact factor: 3.295

8.  Adult Migraine Hospital Admission Trends in Finland: A Nationwide Registry Study.

Authors:  Jussi O T Sipilä; Jori O Ruuskanen; Päivi Rautava; Ville Kytö
Journal:  J Clin Med       Date:  2020-01-23       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.